2-FEA: Difference between revisions

(19 intermediate revisions by 11 users not shown)

Line 1:

~~{{headerpanel|{{Approval}}}}~~

'''2-Fluoroethamphetamine''' ('''2-FEA''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::amphetamine]] class that produces classical stimulant effects such as [[stimulation]], [[focus enhancement|enhanced focus]] and [[euphoria]] when [[route of administration|administered]].

'''2-Fluoroethamphetamine''' ('''2-FEA''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::Substituted amphetamine|amphetamine]] class that produces classical stimulant effects such as [[stimulation]], [[focus enhancement|enhanced focus]] and [[euphoria]] when [[route of administration|administered]].

~~Anecdotal reports suggest that~~ 2-FEA ~~has been compared with [[3-FEA]], which it is thought to share many of~~ its ~~effects~~ with.

The exact effects of 2-FEA are not well known by its users with anecdotal reports suggesting only minimal activity and possible serotonergic qualities.

2-FEA is sold on the online [[research chemical]] market. It is strongly advised to use [[harm reduction practices]] if using this substance.

Line 15:

Line 14:

==Pharmacology==

~~{{pharmacology}}~~

2-FEA has not yet been formally studied to the same extent as traditional [[amphetamines]]. Currently, it is assumed that it most likely acts primarily as a triple [[Reuptake inhibitor|reuptake inhibitor]], and that it releases the neurotransmitters: [[serotonin]], [[dopamine]], and [[norepinephrine]]. 2-FEA likely creates it effects by acting as a releasing agent of said neurotransmitters and/or by binding to- and partially blocking the transporter proteins that normally clear substances from the [[Synaptic cleft|synaptic cleft,]] after they have fulfilled their function of conducting a neural impulse.<ref>{{cite journal | vauthors=((Tessel, R. E.)), ((Woods, J. H.)) | journal=The Journal of Pharmacology and Experimental Therapeutics | title=Substituted N-ethylamphetamine self injection responding in the rhesus monkey: structure-activity relationships | volume=205 | issue=2 | pages=274–281 | date= May 1978 | issn=0022-3565}}</ref>

~~Although~~ 2-FEA has not been formally studied on the same ~~level~~ as traditional [[amphetamines]], it is ~~roughly~~ assumed that it most likely acts primarily as a triple [[reuptake inhibitor]] and~~/or [[releaser]] of~~ the ~~[[monoamine]] [[~~neurotransmitters]] [[serotonin]], [[dopamine]], and [[norepinephrine]].

~~This indicates that~~ 2-FEA ~~effectively increases the levels of all the three major [[monoamine neurotransmitters]] dopamine, norepinephrine, and serotonin in the brain~~ by acting as a releasing agent of said neurotransmitters and/or by binding to and partially ~~[[Reuptake inhibitor|~~blocking the transporter proteins]] that normally clear ~~those molecules~~ from the [[synaptic cleft]] after they have fulfilled their function of conducting a neural impulse. ~~This transporter blockade allows these molecules to accumulate within core synaptic regions~~ of the ~~brain to extra~~-~~endogenous levels, resulting in a combination of [[Muscle relaxation~~|~~relaxing]], [[stimulating]], [[disinhibition~~|~~disinhibiting]] and [[euphoria~~|~~euphoric]] effects associated with [[entactogenic]] [[substituted amphetamines]] such as [[MDMA]] or [[4~~-~~FA]].{{citation needed~~}}

==Subjective effects==

~~In comparison to other substituted amphetamines,~~ 2-FEA ~~is thought~~ to be relatively free of side effects ~~such as~~ [[~~nausea]], [[high blood pressure~~]], ~~[[anxiety]] and~~ an ~~uncomfortable [[offset]] ("comedown"), when comsumed~~ in ~~low to moderate doses. The experience is also reported to be less a stimulating and more euphoric in a fashion that is also more compareable to~~ [[3-FEA~~]] than to [[2-FMA~~]].

The effects of 2-FEA appear to be very subtle and difficult to characterize. Some reports suggest it is relatively mild and free of side effects in a similar fashion to [[2-FA]], while others note an increase in physical side effects or serotonergic activity reminiscent of [[3-FEA]].

Line 27:

Line 23:

|{{effects/physical|

*'''[[Effect::Stimulation]]''' - 2-FEA ~~has been~~ reported to produce a paradoxical combination of sedating and ~~stimulatory~~ effects~~, with the~~ sedating aspects ~~believed to be~~ attributable to ~~the believed~~ serotonin ~~it releases~~. The ~~stimulatory~~ effects are typically more prominent at dosages in and above the strong dosage range and tend to become prominent after the peak effects ~~of a dose~~ have subsided.

*'''[[Effect::Stimulation]]''' and '''[[Effect::Sedation]]''' - 2-FEA is reported to produce a paradoxical combination of sedating and stimulating effects. The sedating aspects are perhaps attributable to serotonin release. The stimulating effects are typically more prominent at dosages in and above the strong dosage range and tend to become prominent after the peak effects have subsided.

*'''[[Effect::Physical euphoria]]'''

*'''[[Effect::Tactile enhancement]]'''

Line 61:

Line 57:

}}

|{{effects/cognitive|

The cognitive effects of 2-FEA are generally very subtle and consist of mild to moderate stimulation.

*'''[[Effect::Analysis enhancement]]'''

*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect typically occurs with overly high doses or after redosing and staying awake for extended periods of time.

Line 96:

Line 94:

}}

===Experience reports===

~~Anecdotal reports which describe the effects of this compound within our [[experience index]] include:~~

{{Experience reports|erowid_experience_substance_label=2-Fluoroethamphetamine}}

{{~~#ask: [[Category:2-FEA]][[Category:~~Experience]]|~~format~~=~~ul|Columns=1~~}}

==Toxicity and harm potential==

Line 117:

Line 115:

===Dangerous interactions===

*'''[[Stimulants]]''' - 2-FEA can be potentially dangerous in combination with other [[stimulant]]s as it can [[increased heart rate|increase one's heart rate]] and [[increased blood pressure|blood pressure]] to dangerous levels.

*'''[[DangerousInteraction::Stimulants]]''' - 2-FEA can be potentially dangerous in combination with other [[stimulant]]s as it can [[increased heart rate|increase one's heart rate]] and [[increased blood pressure|blood pressure]] to dangerous levels.

*'''[[MDMA]]''' - The neurotoxic effects of MDMA may be increased when combined with [[amphetamine]]s.

*'''[[DangerousInteraction::MDMA]]''' - The neurotoxic effects of MDMA may be increased when combined with [[amphetamine]]s.

*'''[[Cocaine]]''' - This combination may increase strain on the heart.

*'''[[DangerousInteraction::Cocaine]]''' - This combination may increase strain on the heart.

==Legal status==

Line 127:

2-FEA is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

*'''Canada:''' 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.<ref>Controlled Drugs and Substances Act ~~(S.C. 1996, c. 19)~~ |~~http~~://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>

*'''Canada''': 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref>

*'''New Zealand:''' 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>~~http~~://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html~~#DLM436576~~</ref>

*'''France''': As of december 2024, 2-FEA is not explicitly scheduled. It is thus legal to possess, although in a grey area.<ref>{{Citation | title=Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants | url=https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/}}</ref>

*'''United Kingdom:''' 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>Misuse of Drugs Act 1971 ~~(Legislation.gov.uk)~~ |~~http~~://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I</ref>

*'''Germany''': 2-FEA is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 19, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref>

*'''New Zealand''': 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref>

*'''The Netherlands:''' 2-FEA is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). <ref>{{Citation|title= Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch) | year=2024|url=https://www.tweedekamer.nl/kamerstukken/wetsvoorstellen/detail?id=2022Z14042&dossier=36159}}</ref>

*'''Switzerland''': 2-FEA can be considered a controlled substance as a defined derivative of a-methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>

*'''United Kingdom''': 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>{{Citation | title=Misuse of Drugs Act 1971 | url=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I}}</ref>

==See also==

*[[Responsible use]]

*[[Research chemical]]

Line 138:

Line 143:

*[[3-FEA]]

~~<!--~~==External links==

==External links==

*[https://isomerdesign.com/PiHKAL/explore.php?id=2299 3-FEA (Isomer Design)]

~~-->~~

==References==

[[Category:Psychoactive substance]]

[[Category:Stimulant]]

[[Category:Amphetamine]]

[[Category:Research chemical]]

~~[[Category:Amphetamine]]~~

~~[[Category:Stimulant]]~~

@@ Line 1: / Line 1: @@
-{{headerpanel|{{Approval}}}}
 {{SummarySheet}}
 {{SubstanceBox/2-FEA}}
-'''2-Fluoroethamphetamine''' ('''2-FEA''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::amphetamine]] class that produces classical stimulant effects such as [[stimulation]], [[focus enhancement|enhanced focus]] and [[euphoria]] when [[route of administration|administered]].
+'''2-Fluoroethamphetamine''' ('''2-FEA''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::Substituted amphetamine|amphetamine]] class that produces classical stimulant effects such as [[stimulation]], [[focus enhancement|enhanced focus]] and [[euphoria]] when [[route of administration|administered]].
-Anecdotal reports suggest that 2-FEA has been compared with [[3-FEA]], which it is thought to share many of its effects with.
+The exact effects of 2-FEA are not well known by its users with anecdotal reports suggesting only minimal activity and possible serotonergic qualities.
 -FEA is sold on the online [[research chemical]] market. It is strongly advised to use [[harm reduction practices]] if using this substance.
@@ Line 15: / Line 14: @@
 ==Pharmacology==
-{{pharmacology}}
+-FEA has not yet been formally studied to the same extent as traditional [[amphetamines]]. Currently, it is assumed that it most likely acts primarily as a triple [[Reuptake inhibitor|reuptake inhibitor]], and that it releases the neurotransmitters: [[serotonin]], [[dopamine]], and [[norepinephrine]]. 2-FEA likely creates it effects by acting as a releasing agent of said neurotransmitters and/or by binding to- and partially blocking the transporter proteins that normally clear substances from the [[Synaptic cleft|synaptic cleft,]] after they have fulfilled their function of conducting a neural impulse.<ref>{{cite journal | vauthors=((Tessel, R. E.)), ((Woods, J. H.)) | journal=The Journal of Pharmacology and Experimental Therapeutics | title=Substituted N-ethylamphetamine self injection responding in the rhesus monkey: structure-activity relationships | volume=205 | issue=2 | pages=274–281 | date= May 1978 | issn=0022-3565}}</ref>
-Although 2-FEA has not been formally studied on the same level as traditional [[amphetamines]], it is roughly assumed that it most likely acts primarily as a triple [[reuptake inhibitor]] and/or [[releaser]] of the [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]], and [[norepinephrine]].
-This indicates that 2-FEA effectively increases the levels of all the three major [[monoamine neurotransmitters]] dopamine, norepinephrine, and serotonin in the brain by acting as a releasing agent of said neurotransmitters and/or by binding to and partially [[Reuptake inhibitor|blocking the transporter proteins]] that normally clear those molecules from the [[synaptic cleft]] after they have fulfilled their function of conducting a neural impulse. This transporter blockade allows these molecules to accumulate within core synaptic regions of the brain to extra-endogenous levels, resulting in a combination of [[Muscle relaxation|relaxing]], [[stimulating]], [[disinhibition|disinhibiting]] and [[euphoria|euphoric]] effects associated with [[entactogenic]] [[substituted amphetamines]] such as [[MDMA]] or  [[4-FA]].{{citation needed}}
 ==Subjective effects==
-In comparison to other substituted amphetamines, 2-FEA is thought to be relatively free of side effects such as [[nausea]], [[high blood pressure]], [[anxiety]] and an uncomfortable [[offset]] ("comedown"), when comsumed in low to moderate doses. The experience is also reported to be less a stimulating and more euphoric in a fashion that is also more compareable to [[3-FEA]] than to [[2-FMA]].
+The effects of 2-FEA appear to be very subtle and difficult to characterize. Some reports suggest it is relatively mild and free of side effects in a similar fashion to [[2-FA]], while others note an increase in physical side effects or serotonergic activity reminiscent of [[3-FEA]].
 {{Preamble/SubjectiveEffects}}
@@ Line 27: / Line 23: @@
 |{{effects/physical|
-*'''[[Effect::Stimulation]]''' - 2-FEA has been reported to produce a paradoxical combination of sedating and stimulatory effects, with the sedating aspects believed to be attributable to the believed serotonin it releases. The stimulatory effects are typically more prominent at dosages in and above the strong dosage range and tend to become prominent after the peak effects of a dose have subsided.
+*'''[[Effect::Stimulation]]''' and '''[[Effect::Sedation]]''' - 2-FEA is reported to produce a paradoxical combination of sedating and stimulating effects. The sedating aspects are perhaps attributable to serotonin release. The stimulating effects are typically more prominent at dosages in and above the strong dosage range and tend to become prominent after the peak effects have subsided.
 *'''[[Effect::Physical euphoria]]'''
 *'''[[Effect::Tactile enhancement]]'''
@@ Line 61: / Line 57: @@
 }}
 |{{effects/cognitive|
+The cognitive effects of 2-FEA are generally very subtle and consist of mild to moderate stimulation.
 *'''[[Effect::Analysis enhancement]]'''
 *'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect typically occurs with overly high doses or after redosing and staying awake for extended periods of time.
@@ Line 96: / Line 94: @@
 }}
 }}
 ===Experience reports===
-Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
+{{Experience reports|erowid_experience_substance_label=2-Fluoroethamphetamine}}
-{{#ask: [[Category:2-FEA]][[Category:Experience]]|format=ul|Columns=1}}
 ==Toxicity and harm potential==
@@ Line 117: / Line 115: @@
 ===Dangerous interactions===
 {{DangerousInteractions/Intro}}
-*'''[[Stimulants]]''' - 2-FEA can be potentially dangerous in combination with other [[stimulant]]s as it can [[increased heart rate|increase one's heart rate]] and [[increased blood pressure|blood pressure]] to dangerous levels.
+*'''[[DangerousInteraction::Stimulants]]''' - 2-FEA can be potentially dangerous in combination with other [[stimulant]]s as it can [[increased heart rate|increase one's heart rate]] and [[increased blood pressure|blood pressure]] to dangerous levels.
 {{DangerousInteractions/Stimulants}}
-*'''[[MDMA]]''' - The neurotoxic effects of MDMA may be increased when combined with [[amphetamine]]s.
+*'''[[DangerousInteraction::MDMA]]''' - The neurotoxic effects of MDMA may be increased when combined with [[amphetamine]]s.
 {{DangerousInteractions/MAOI|nt=dopamine}}
-*'''[[Cocaine]]''' - This combination may increase strain on the heart.
+*'''[[DangerousInteraction::Cocaine]]''' - This combination may increase strain on the heart.
 ==Legal status==
@@ Line 127: / Line 127: @@
 -FEA is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
-*'''Canada:''' 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
+*'''Canada''': 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref>
-*'''New Zealand:''' 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>
+*'''France''': As of december 2024, 2-FEA is not explicitly scheduled. It is thus legal to possess, although in a grey area.<ref>{{Citation | title=Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants  | url=https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/}}</ref>
-*'''United Kingdom:''' 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I</ref>
+*'''Germany''': 2-FEA is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 19, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref>
+*'''New Zealand''': 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref>
+*'''The Netherlands:''' 2-FEA is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). <ref>{{Citation|title= Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch) | year=2024|url=https://www.tweedekamer.nl/kamerstukken/wetsvoorstellen/detail?id=2022Z14042&dossier=36159}}</ref>
+*'''Switzerland''': 2-FEA can be considered a controlled substance as a defined derivative of a-methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
+*'''United Kingdom''': 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.<ref>{{Citation | title=Misuse of Drugs Act 1971 | url=https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I}}</ref>
 ==See also==
 *[[Responsible use]]
 *[[Research chemical]]
@@ Line 138: / Line 143: @@
 *[[3-FEA]]
-<!--==External links==
+==External links==
+*[https://isomerdesign.com/PiHKAL/explore.php?id=2299 3-FEA (Isomer Design)]
--->
 ==References==
-<references/>
+<references />
 [[Category:Psychoactive substance]]
+[[Category:Stimulant]]
+[[Category:Amphetamine]]
 [[Category:Research chemical]]
-[[Category:Amphetamine]]
-[[Category:Stimulant]]
 {{#set:Featured=true}}